The potential of selenium supplements provided as selenium-enriched dairy protein or yeast selenium to improve selenium status

Phase 4

Completed

• Conditions: Plasma selenium concentration Levels of biomarkers in rectal epithelium; Plasma selenium concentration; Levels of biomarkers in rectal epithelium; Diet and Nutrition - Other diet and nutrition disorders

• Registration Number: ACTRN12607000345482
• Lead Sponsor: Professor Graeme Young MD, FRACP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-06-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Healthy, with no active bowel disease, orWith a previous history of adenoma removal >6 months ago, With plasma selenium at or below 100 µg/dL. (to ensure that people with a High background selenium status are not included in the study),

Exclusion Criteria

Any allergy or intolerance to milk/dairy productsPlasma Se above the 95th percentile of the current population (i.e. >100µg/dL)Evidence of any active mucosal bowel disease, eg colitis, or of malabsorption.With no evidence of any other active clinical disease precluding participation in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of plasma glutathione peroxidase (GSPx), plasma selenium concentration & plasma selenoprotein P[Taken at fortnightly intervals throughout the study ];Level of biomarkers in rectal epithelium including selected endpoints from selenium concentration and Glutathione Peroxidase (GSPx)[Taken at commencement & end of intervention (week 0 & week 6) & at end of 6wk follow on/wash out period]

Secondary Outcome Measures

Name	Time	Method
evel of biomarkers in rectal epithelium. They include selenium concentration and thioredoxin reductase and glutathione peroxidase activities, and histologically: PCNA cell proliferation and apoptosis rates, and p53 immunohistochemical staining. [Taken at commencement & end of intervention (week 0 & week 6) & at end of 6wk follow on/wash out period];Level of biomarkers in blood taken, including plasma Se, GSPx & selenoprotein P.[At fortnightly intervals throughout the study.]